712 North is a biopharma founded at UCSF around a novel, proprietary mitochondrial target protease crucial for neuronal survival. The target is highly validated and supported by in vivo data for Alzheimer’s disease. Knock-out of the protease can protect against neurodegeneration. We are part of a larger network of strategic alliances between biotech companies, patient organizations, and academic institutions in the San Francisco Bay Area. For selected programs in our pipeline we are interested in discussing co-development, partial or global in- and out-licensing.